Lisata Therapeutics (LSTA) Stock Price, News & Analysis

Company Overview

Lisata Therapeutics, Inc. (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies. To advance its programs, the company collaborates with academic institutions and contract research organizations, supporting clinical studies and translational research efforts in North America and Europe.

Headquartered in the United States, Lisata Therapeutics is governed by a leadership team with experience in biotechnology research, clinical operations and regulatory affairs. The company’s board and scientific advisors bring expertise in immunology, drug development and commercial strategy to support its mission of addressing unmet medical needs.

Key Stats

• Today's Range: $3.20 to $3.30
• 50-Day Range: $2.83 to $5.04
• 52-Week Range: $1.81 to $5.07
• Volume: 43,830 shs
• Average Volume: 96,900 shs
• Market Capitalization: $29.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Hold

Lisata Therapeutics Stock Analysis - MarketRank™

Lisata Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 724th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Lisata Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Lisata Therapeutics has a consensus price target of $15.00, representing about 360.1% upside from its current price of $3.26.

Amount of Analyst Coverage

Lisata Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lisata Therapeutics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lisata Therapeutics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lisata Therapeutics has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.63% of the float of Lisata Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lisata Therapeutics has a short interest ratio ("days to cover") of 0.51, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lisata Therapeutics has recently increased by 204.95%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lisata Therapeutics does not currently pay a dividend.

Dividend Growth

Lisata Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Lisata Therapeutics this week, compared to 2 articles on an average week.

Search Interest

8 people have searched for LSTA on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.60% of the stock of Lisata Therapeutics is held by insiders.

Percentage Held by Institutions

8.94% of the stock of Lisata Therapeutics is held by institutions.

LSTA Stock Analysis - Frequently Asked Questions

How have LSTA shares performed this year?

Lisata Therapeutics' stock was trading at $1.86 at the beginning of 2026. Since then, LSTA stock has increased by 75.3% and is now trading at $3.26.

How were Lisata Therapeutics' earnings last quarter?

Lisata Therapeutics, Inc. (NASDAQ:LSTA) posted its quarterly earnings results on Thursday, March, 12th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.41. The firm had revenue of $0.10 million for the quarter.

Who are Lisata Therapeutics' major shareholders?

Lisata Therapeutics' top institutional shareholders include Deltec Asset Management LLC (1.00%) and SOL Capital Management CO (0.13%).

How do I buy shares of Lisata Therapeutics?

Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lisata Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lisata Therapeutics investors own include PayPal (PYPL), JD.com (JD), NIO (NIO), Construction Partners (ROAD), Sunrun (RUN), ASE Technology (ASX) and Coinbase Global (COIN).

Company Calendar

• Last Earnings: 3/12/2026
• Today: 5/07/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LSTA
• CIK: 320017
• Web: www.caladrius.com
• Phone: (908) 842-0100
• Fax: 646-514-7787
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Lisata Therapeutics: $15.00
• High Price Target: $15.00
• Low Price Target: $15.00
• Potential Upside/Downside: +360.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.59 million
• Net Margins: N/A
• Pretax Margin: -10,322.35%
• Return on Equity: -85.50%
• Return on Assets: -70.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.76
• Quick Ratio: 5.76

Sales & Book Value

• Annual Sales: $170 thousand
• Price / Sales: 174.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.66 per share
• Price / Book: 1.96

Miscellaneous

• Outstanding Shares: 9,106,000
• Free Float: 8,232,000
• Market Cap: $29.69 million
• Optionable: Not Optionable
• Beta: 0.81